RTRX - レトロフィン (Retrophin Inc.) レトロフィン

 RTRXのチャート


 RTRXの企業情報

symbol RTRx
会社名 Retrophin Inc. (レトロフィン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 レトロフィン(Retrophin Inc.)はバイオ医薬品会社である。同社は深刻な、破滅的な、またはまれな疾患の治療のための治療法の開発・取得・商業化を行う。同社はChenodal(ケノデオキシコール酸)、Cholbam(コール酸)およびThiola(チオプロニン)を販売する。Chenodalは、病気と高齢のために手術が容認できない健康上の危険をもたらす胆石に苦しむ患者の治療のために米国で承認される。また、脳動脈瘤症(CTX)患者のケアに使用される。Cholbamは、単一の酵素欠損に起因する胆汁酸合成障害の治療のために米国で承認され、またペルオキシソーム障害の患者の補助治療が適応される。Thiolaは、重度の同型接合性シスチン尿症患者のシスチン(腎臓)結石の予防のために米国で承認される。   レトロフィンは、米国のバイオ医薬品企業。消耗性疾患や致死的疾患の治療法の開発、商業化を手掛ける。胆石の治療薬Chenodalと、高血圧症の治療薬Vecamylを販売するほか、統合失調症と自閉症の治療向け点鼻薬シントシノンの開発を行う。また乳児痙攣やネフロ―ゼ症候群の治療薬や、パントテン酸キナ―ゼ関連神経変性の治療薬の開発を手掛ける。   Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
本社所在地 3721 Valley Centre Drive Suite 200 San Diego CA 92130 USA
代表者氏名 Gary A. Lyons ゲイリー・A・ライオンズ
代表者役職名 Independent Chairman of the Board
電話番号 +1 760-260-8600
設立年月日 39479
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 173人
url www.retrophin.com
nasdaq_url https://www.nasdaq.com/symbol/rtrx
adr_tso
EBITDA EBITDA(百万ドル) -44.42900
終値(lastsale) 26.14
時価総額(marketcap) 1068059853.96
時価総額 時価総額(百万ドル) 122.392
売上高 売上高(百万ドル) 162.28600
企業価値(EV) 企業価値(EV)(百万ドル) 812.10700
当期純利益 当期純利益(百万ドル) -75.11900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Retrophin Inc revenues increased 10% to $79.8M. Net loss increased 67% to $40.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 59% to $55.7M (expense) Selling/General/Admin. Expense increase of 5% to $36.2M (expense) Other income (expense).

 RTRXのテクニカル分析


 RTRXのニュース

   Retrophin Appoints Suzanne L. Bruhn, Ph.D. to Board of Directors | MarketScreener  2020/04/09 20:31:08 MarketScreener
SAN DIEGO, April 09, 2020 -- Retrophin, Inc. today announced the appointment of Suzanne L. Bruhn, Ph.D. to the Company’s Board of Directors, effective immediately. Dr. Bruhn brings… | April 9, 2020
   Do Options Traders Know Something About Retrophin (RTRX) Stock We Don't?  2020/03/18 14:01:00 Zacks Investment Research
Investors need to pay close attention to Retrophin (RTRX) stock based on the movements in the options market lately.
   Earnings Preview: Retrophin (RTRX) Q3 Earnings Expected to Decline  2019/10/23 14:34:01 Zacks Investment Research
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris  2019/09/10 11:36:12 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) ( reacted to positive Nuplazid data) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Scpharmaceuticals Inc (NASDAQ: SCPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Pfenex Inc (NYSE: PFNX ) Down In The Dumps (Biotech stocks that hit 52-week lows on Sept. 9.) Advaxis, Inc. (NASDAQ: ADXS ) (reacted to third-quarter results) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Endologix, Inc. (NASDAQ: ELGX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Illumina, Inc. (NASDAQ: ILMN ) Neurotrope Inc (NASDAQ: NTRP ) ( Alzheimer's disease drug did not meet the primary endpoint) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Retrophin Inc (NASDAQ: RTRX ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Trinity Biotech plc (NASDAQ: TRIB ) Transenterix Inc (NYSE: TRXC ) See also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Translate Bio Discontinues Development Of mRNA Therapy Translate Bio Inc (NASDAQ: TBIO ) said in a clinical pipeline update that it has decided to discontinue the development of MRT5201, a liver-targeted treatment for ornithine transcarbamylase, or OTC, deficiency.
   Retrophin Down on Neurological Disorder Drug Study Failure  2019/08/23 11:38:00 Zacks Investment Research
Retrophin (RTRX) declines as the late-stage study on a rare neurological disorder candidate failed to achieve its main goal.
   Earnings Preview: Retrophin (RTRX) Q3 Earnings Expected to Decline  2019/10/23 14:34:01 Zacks Investment Research
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris  2019/09/10 11:36:12 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) ( reacted to positive Nuplazid data) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Scpharmaceuticals Inc (NASDAQ: SCPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Pfenex Inc (NYSE: PFNX ) Down In The Dumps (Biotech stocks that hit 52-week lows on Sept. 9.) Advaxis, Inc. (NASDAQ: ADXS ) (reacted to third-quarter results) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Endologix, Inc. (NASDAQ: ELGX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Illumina, Inc. (NASDAQ: ILMN ) Neurotrope Inc (NASDAQ: NTRP ) ( Alzheimer's disease drug did not meet the primary endpoint) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Retrophin Inc (NASDAQ: RTRX ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Trinity Biotech plc (NASDAQ: TRIB ) Transenterix Inc (NYSE: TRXC ) See also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Translate Bio Discontinues Development Of mRNA Therapy Translate Bio Inc (NASDAQ: TBIO ) said in a clinical pipeline update that it has decided to discontinue the development of MRT5201, a liver-targeted treatment for ornithine transcarbamylase, or OTC, deficiency.
   Retrophin Down on Neurological Disorder Drug Study Failure  2019/08/23 11:38:00 Zacks Investment Research
Retrophin (RTRX) declines as the late-stage study on a rare neurological disorder candidate failed to achieve its main goal.
   Shkreli-Founded Biotech Seen Ripe for Buying as Shares Tumble  2019/08/22 14:42:40 Yahoo Finance
(Bloomberg) -- Retrophin Inc. shares plummeted as much as 32% in early trading on Thursday after an experimental therapy from the drugmaker missed the main and key secondary goals in a late-stage study. That may signal an opportunity to pick up shares, according to one analyst.“Selloff overdone, buy,
   Why Are Shares Of Small-Cap Biotech Retrophin Plunging To A Multiyear Low?  2019/08/22 14:08:21 Benzinga
Retrophin Inc (NASDAQ: RTRX ) shares were plummeting Thursday following an adverse clinical readout from the company. What Happened The small-cap biotech announced that a Phase 3 study dubbed FORT did not meet its primary endpoint, showing no difference between the treatment arm and the control arm. The study is evaluating the safety and efficacy of fosmetpantotenate in patients with pantothenate kinase-associated neurodegeneration, or PKAN. PKAN is a disorder of the nervous system resulting from an abnormal buildup of iron in certain areas of brain, and it is characterized by progressive difficulty … Full story available on Benzinga.com
   Barclays likes Genfit in premarket analyst action  2019-04-22
Genfit (NASDAQ: GNFT ) initiated with Overweight rating and $55 (120% upside) price target at Barclays. More news on: Genfit SA, Acceleron Pharma Inc., Retrophin, Inc., Healthcare stocks news, Read more …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 レトロフィン RTRX Retrophin Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)